ProCanBio

ProCanBio aggregates curated biomarker data for prostate cancer to support biomarker discovery and translational research.

Key Features:

• Extensive Biomarker Compilation: Contains 2,053 potential prostate cancer biomarkers compiled from 412 scientific publications.
• Biomarker Types: Includes 766 protein-based, 488 RNA-based, 157 genomic mutations, 261 miRNA-based, and 122 metabolite-based biomarkers.
• Curated Literature Source: Biomarker entries are derived from manual curation of peer-reviewed publications.

Scientific Applications:

• Tumorigenesis Research: Supports studies elucidating molecular mechanisms of prostate tumorigenesis through aggregated biomarker evidence.
• Biomarker Identification and Validation: Facilitates selection and cross-reference of candidate biomarkers for diagnostic and prognostic validation.
• Precision Medicine and Therapeutics: Provides consolidated biomarker data to inform biomarker-driven patient stratification and targeted therapeutic strategies.

Methodology:

Data were manually curated from 412 scientific publications and compiled into a database of 2,053 biomarkers categorized as protein-, RNA-, genomic mutation-, miRNA-, and metabolite-based.